产品名称
抗His-Tag嵌合抗体，人，单克隆, recombinant, expressed in HEK 293 cells, clone RMH01, purified immunoglobulin
recombinant
expressed in HEK 293 cells
antibody form
purified immunoglobulin
antibody product type
primary antibodies
clone
RMH01, monoclonal
recombinant monoclonal
form
buffered aqueous glycerol solution
technique(s)
capture ELISA: 0.1-2 μg/mL
western blot: 0.1-1 μg/mL
isotype
IgG
shipped in
wet ice
storage temp.
−20°C
target post-translational modification
unmodified
Quality Level
Biochem/physiol Actions
该抗体是一种人兔嵌合抗体，是通过将兔抗His标签单克隆抗体（RM146）的抗原结合区（重链和轻链的可变域、VH和VL的可变域）与人IgG1的恒定域融合而制成的。该抗体仅可被抗人IgG二抗识别。
Disclaimer
除非我们的产品目录或产品附带的其他公司文档另有说明，否则我们的产品仅供研究使用，不得用于任何其他目的，包括但不限于未经授权的商业用途、体外诊断用途、离体或体内治疗用途或任何类型的消费或应用于人类或动物。
Features and Benefits
完放心地使用我们的抗体。如果抗体在您的申请的研究中不起作用，我们将全额退款或安排替代抗体。了解更多信息。
General description
六组氨酸标签（His-tag）由四到六个通过基因融合的组氨酸组成。它被广泛用于通过固定化金属离子亲和层析（IMAC）对蛋白进行纯化。
Immunogen
在N端带有6xHis标签的肽与在C端带有6xHis标签的另一种肽的混合物。
Physical form
溶于含有50％甘油、1％BSA和0.09％叠氮化钠的磷酸盐缓冲盐水中。
未找到合适的产品？
试试我们的产品选型工具.
存储类别
10 - Combustible liquids
wgk
WGK 2
法规信息
常规特殊物品
此项目有
Jonathan F Lovell et al.
BMC medicine, 20(1), 462-462 (2022-11-30)
Numerous vaccine strategies are being advanced to control SARS-CoV-2, the cause of the COVID-19 pandemic. EuCorVac-19 (ECV19) is a recombinant protein nanoparticle vaccine that displays the SARS-CoV-2 receptor-binding domain (RBD) on immunogenic nanoliposomes. Initial study of a phase 2 randomized
Tandem immobilized metal-ion affinity chromatography/immunoaffinity purification of His-tagged proteins?evaluation of two anti-His-tag monoclonal antibodies
Muller KM, et al.
Analytical Biochemistry, 259(1), 54-61 (1998)
Loree Heller et al.
Journal of cellular and molecular medicine, 24(15), 8772-8778 (2020-07-02)
In neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, multiple sclerosis and amyotrophic lateral sclerosis, neuroinflammation can lead to blood-brain barrier (BBB) breakdown. After intravenous or intra-arterial injection into mice, endothelial progenitor cells (EPCs) home to the damaged BBB to
Reynald Thinard et al.
Pharmaceutics, 14(7) (2022-07-28)
The failures of anti-β-amyloid immunotherapies suggested that the very low fraction of injected antibodies reaching the brain parenchyma due to the filtering effect of the BBB may be a reason for the lack of therapeutic effect. However, there is no
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持